New drugs for treatment of attention-deficit/hyperactivity disorder

Expert Opinion on Emerging Drugs

Volumn 7, Issue 2, 2002, Pages 269-276

  Chung, Bowen ^a   Suzuki, Alejandra R ^a   McGough, James J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amphetamine; Atomoxetine; Attention deficit hyperactivity disorder; Medication treatment; Methylphenidate

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ANTIHYPERTENSIVE AGENT; ATOMOXETINE; CENTRAL STIMULANT AGENT; DESIPRAMINE; DEXAMPHETAMINE; DEXEDRINE SPANSULE; DEXMETHYLPHENIDATE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMATE RECEPTOR AGONIST; GW 320659 A; HISTAMINE AGONIST; MANIFAXINE; METHYLPHENIDATE; NICOTINIC AGENT; NORTRIPTYLINE; PEMOLINE; PEMOLINE MAGNESIUM; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ANOREXIA; ANXIETY; ATTENTION DEFICIT DISORDER; BRAIN REGION; CLINICAL TRIAL; DOPAMINERGIC ACTIVITY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FRONTAL CORTEX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; LIVER FAILURE; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; SIDE EFFECT; TACHYCARDIA;

EID: 0036844358     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.7.2.269     Document Type: Review

References (52)

1. Robison LM, Sclar DA, Galin RS: National trends in the prevalence of attention - Deficit disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr. (1999) 38:209-217.
2. Barkley RA, Fischer M, Smallish L, Fletcher K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol. (2002) 111:279-282.
3. Wilens TE, Biederman J, Spencer TJ: Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev. Med. (2002). 53:113-131. Excellent current review article on ADHD.
4. Barkley R: Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd Edition. Guilford Press. New York (1998). Outstanding textbook summarising ADHD research.
5. Chan E, Zhan C, Homer CJ: Health care use and costs for children with attention deficit/hyperactivity disorder: National estimates from the medical expenditure panel survey. Arch. Pediatr. Adolesc. Med. (2002) 156:504-511.
6. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Text Revision (DSM-IV-TR). American Psychiatric Association Press, Washington, DC (2000).
7. Applegate B, Lahey BB, Hart EL et al: Validity of the age-of-onset criterion for ADHD: A report from the DSM-IV field trials. J. Am. Acad. Child Adolesc. Psychiatry (1997) 36:1211-1221.
8. Brown RT, Freeman WS, Perrin JM et al.: Prevalence and assessment of attention deficit/hyperactivity disorder in primary care settings. Pediatrics (2001) 107:E43.
9. Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J. Clin. Psychiatry (1998) 59(Suppl. 7):50-58.
10. Biederman J, Wilens T, Mick E, Faraone SV, Spencer T: Does attention deficit hyperactivity disorder impact the developmental course of drug and alcohol abuse and dependence? Biol. Psychiatry (1998) 44:269-273.
11. Biederman J, Wilens T, Mick E, Milberger S, Spencer T, Faraone S: Psychoactive substance use disorder in adults with attention deficit hyperactivity disorder: Effects of ADHD and psychiatric comorbidity. Am. J. Psychiatry (1995) 152:1652-1658.
12. McGuffin P, Riley B, Plomin R: Toward behavioral genomics. Science (2001) 291:1243-1249.
13. Faraone SV: Genetics of child disorders: XX. ADHD, part 4: Is ADHD genetically heterogenous? J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:1455-1457.
14. Milberger S, Biederman J, Faraone SV, Chen L, Jones J: Is maternal smoking a risk factor for attention deficit hyperactivity disorder in children? Am. J. Psychiatry. (1996) 153:1138-1142.
15. Tuthill RW: Hair lead levels related to children's classroom attention-deficit behavior. Arch. Environ. Health. (1996) 51:363-383.
16. Sunohara GA, Roberts W, Malone M et al.: Linkage of the dopamine D4 receptor gene and attention-deficit/hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (2000) 39:1537-1542.
17. Daly G, Hawi Z, Fitzgerald M, Gill M: Mapping susceptibility loci in attention deficit hyperactivity disorder: Preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry (1999) 4:192-196.
18. Fisher SE, Francks C, McCracken JT et al.: A genomewide scan for loci involved in attention-deficit/hyperactivity disorder. Am. J. Hum. Genet. (2002) 70:1183-1196. First genomic scan of ADHD.
19. Leibson CL, Katusic SK, Barbaresi WJ, Ransom J, O'Brien PC: Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA (2001) 285:60-66. Seminal article on health services usage for children with ADHD.
20. Guevara J, Lozano P, Wickizer T, Mell L, Gephart H: Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 108:71-78.
21. Barkley RA, Murphy KR, Kwasnik D: Motor vehicle driving competencies and risks in teens and young adults with attention deficit hyperactivity disorder. Pediatrics (1996) 98:1089-1095.
22. Szatmari P, Offord DR, Boyle MH: Correlates, associated impairments and patterns of service utilization of children with attention deficit disorder. J. Child Pychol. Psychiatry (1989) 30:205-217
23. Greenhill LL, Halperin JM, Abikoff H: Stimulant medications. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:503-512. Excellent review article on stimulant medications.
24. Barkely RA, McMurray MB, Edelbrock CS et al: Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics (1990) 86:184-192.
25. Spencer T, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE: Growth deficits in ADHD children revisited: Evidence for disorder associated growth delays? J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:1460-1469.
26. Gadow K, Sverd J, Sprafkin J et al.: Long term methylphenidate therapy in children with comorbid attention deficit hyperactivity disorder and chronic multiple tic disorder. Arch. Gen. Psychiatry (1999) 56:330-336.
27. Elia J: Drug treatment for hyperactive children. Therapeutic guidelines. Drugs (1993) 46:863-871.
28. Biederman J, Wilens T, Mick E et al.: Pharmacotherapy of attention deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics (1999) 104:e20.
29. The MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (1999) 56:1073-1086. Landmark study comparing stimulants to behavioural treatments for ADHD.
30. Pelham WE, Gnagy EM, Burrows-MaClean L et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics (2001) 107:e105.
31. Bradley C: The behavior of children receiving benzedrine. Am. J. Psychiatry (1937) 94:577-585.
32. Spencer T, Biederman J, Wilens T et al.: Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J. Am. Acad. Child Adolesc. Psychiatry (1996) 35:409-432.
33. Wilens TE, Biederman J, Prince J et al.: Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am. J. Psychiatry (1996) 153:1147-1153.
34. Spencer T, Biederman J, Coffey B et al.: A double-blind comparison of desipramine and placebo in children and adolescents with chronic tic disorder and comorbid attention-deficit/hyperactivity disorder. Arch. Gen. Psychiatry (2002) 59:649-656.
35. Wilens TE, Spencer TJ, Biederman J et al: A controlled clinical trial of buproprion for attention deficit hyperactivity disorder in adults. Am. J. Psychiatry (2001) 158:282-288.
36. Barrickman LL, Perry PJ, Allen AJ et al.: Buproprion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1995) 34:649-657.
37. Hedges D, Reimherr FW, Rogers A, Strong R, Wender PH: An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder. Pychopharmacol. Bull. (1995) 31:779-783.
38. Findling RL, Schwartz MA, Flannery DJ, Manos MJ: Vetilafaxine in adults with attention-deficit/hyperactivity disorder: An open clinical trial. J. Clin. Psychiatry (1996) 57:184-189.
39. Connor DF, Fletcher KE, Swanson JM: A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry (1999) 38:1551-1559.
40. Steingard R, Biederman J, Spencer T, Wilens T, Gonzalez A: Comparison of clonidine response in the treatment of attention deficit hyperactivity disorder with and without comorbid tic disorders. J. Am. Acad. Child Adolesc. Psychiatry (1993) 32:350-353.
41. Decision Resources INC.: Study on attention-deficit/hyperactivity disorder finds novel psychostimulant formulations will drive market growth. PR Newswire. 30/01/02.
42. Castellanos FX, Elia J, Kruesi MJ et al: Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology (1996) 14:125-137.
43. Solanto MV: Dopamine dysfunction in AD/HD: Integrating clinical and basic neuroscience research. Behav. Brain Res. (2002) 130:65-71.
44. Arnsten AF: Catecholamine regulation of the prefrontal cortex. J. Psychopharmacol (1997) 11:151-162.
45. Rubia K, Overmeyer SO, Taylor E et al.: Hypofrontality in attention deficit hyperactivity disorder during higher order motor control: A study with fMRI. Am. J. Psychiatry (1999) 156:891-896.
46. Volkow ND, Wang G, Fowler JS et al.: Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. (2001) 21:RC121.
47. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K: Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci. Lett. (2000) 285:107-110.
48. Volkow N, Wang G, Fowler J et al.: Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry (1998) 155:1325-1331.
49. Birnbaum SG, Podell DM, Arnsten AF: Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol. Biochem. Behav. (2000) 67:397-403.
50. Biederman J, Spencer T: Attentiondeficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry (1999) 46:1234-1242.
51. Michaelson D, Faries D, Wernicke J et al.: Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, doseresponse study. Pediatrics (2001) 108:E83.
52. Kratochivil CJ, Heiligenstein JH, Dittmann R et al.: Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41:776-784.